New Zealand markets closed

Heron Therapeutics, Inc. (HRTX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.2400-0.0700 (-2.11%)
At close: 04:00PM EDT
3.3000 +0.06 (+1.85%)
After hours: 05:36PM EDT

Heron Therapeutics, Inc.

4242 Campus Point Court
Suite 200
San Diego, CA 92121
United States
858 251 4400

Full-time employees126

Key executives

NameTitlePayExercisedYear born
Mr. Craig Alexander CollardCEO & Director5.49kN/A1966
Ms. Ira DuarteExecutive VP & CFO636.89kN/A1969
Dr. William P. Forbes Pharm. D., Pharm.D.Executive VP & Chief Development Officer734.62kN/A1962
Mr. Ryan CraigVice President of MarketingN/AN/AN/A
Mr. Sean T. RistineSenior Vice President of Human ResourcesN/AN/A1970
Mr. Robert SullivanSenior Vice President of Oncology Care Franchise & Commercial OperationsN/AN/A1978
Jeff CohnExecutive Director, Assistant General Counsel & Assistant SecretaryN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Corporate governance

Heron Therapeutics, Inc.’s ISS governance QualityScore as of 1 July 2024 is 3. The pillar scores are Audit: 6; Board: 3; Shareholder rights: 1; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.